In vivo PET imaging and ex vivo biodistribution studies with [89Zr]Zr-DFOSq-trastuzumab also revealed reduced liver and bone uptake compared with [89Zr]Zr-DFO-NCS-trastuzumab as well as satisfactory HER2 tumour targeting. This evidence concerns the gene ERBB2 and neoplasm.